Cargando…

Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma

Background: A head and neck adenoid-cystic carcinoma is a rare malignant tumor arising from the salivary gland tissues. The long-term survival outcome is poor due to a high risk of recurrences and distant metastasis. The identification of prognostic markers could contribute to a better risk assessme...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedl, Marlene, Stoiber, Stefan, Brkic, Faris F., Kadletz-Wanke, Lorenz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774260/
https://www.ncbi.nlm.nih.gov/pubmed/35052870
http://dx.doi.org/10.3390/biomedicines10010191
_version_ 1784636294729564160
author Friedl, Marlene
Stoiber, Stefan
Brkic, Faris F.
Kadletz-Wanke, Lorenz
author_facet Friedl, Marlene
Stoiber, Stefan
Brkic, Faris F.
Kadletz-Wanke, Lorenz
author_sort Friedl, Marlene
collection PubMed
description Background: A head and neck adenoid-cystic carcinoma is a rare malignant tumor arising from the salivary gland tissues. The long-term survival outcome is poor due to a high risk of recurrences and distant metastasis. The identification of prognostic markers could contribute to a better risk assessment of each patient. The aim of this study is to assess the potential prognostic value of serum albumin in patients with head and neck adenoid-cystic carcinomas. Patients and Methods: This retrospective cohort study included all patients treated for a head and neck adenoid-cystic carcinoma between 1993 and 1 June 2019 with available pretherapeutic albumin values and clinical follow-up data. The cohort was stratified into a high and low group according to the median albumin value. The log-rank test was used for comparing overall and disease-free survival. Results: A total of 37 patients with complete follow-up data and available pretreatment albumin values were available. The overall mortality and recurrence rates were 21.6% (n = 8) and 45.9% (n = 17), respectively. Survival was shorter in the low albumin group. In particular, the mean overall survival for the low and high albumin groups were 121.0 months and 142.8 months, respectively. However, the difference was not statistically significant (p = 0.155). A statistically significant difference was observed in context with disease-free survival (45.2 months, 95% confidence interval 31.7–58.8 months vs. 114.8 months, 95% confidence interval 79.3–150.4 months; p = 0.029). Conclusion: Our study suggests a potential prognostic value of serum albumin in patients with a head and neck ACC. A further, external validation of our results is warranted.
format Online
Article
Text
id pubmed-8774260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87742602022-01-21 Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma Friedl, Marlene Stoiber, Stefan Brkic, Faris F. Kadletz-Wanke, Lorenz Biomedicines Article Background: A head and neck adenoid-cystic carcinoma is a rare malignant tumor arising from the salivary gland tissues. The long-term survival outcome is poor due to a high risk of recurrences and distant metastasis. The identification of prognostic markers could contribute to a better risk assessment of each patient. The aim of this study is to assess the potential prognostic value of serum albumin in patients with head and neck adenoid-cystic carcinomas. Patients and Methods: This retrospective cohort study included all patients treated for a head and neck adenoid-cystic carcinoma between 1993 and 1 June 2019 with available pretherapeutic albumin values and clinical follow-up data. The cohort was stratified into a high and low group according to the median albumin value. The log-rank test was used for comparing overall and disease-free survival. Results: A total of 37 patients with complete follow-up data and available pretreatment albumin values were available. The overall mortality and recurrence rates were 21.6% (n = 8) and 45.9% (n = 17), respectively. Survival was shorter in the low albumin group. In particular, the mean overall survival for the low and high albumin groups were 121.0 months and 142.8 months, respectively. However, the difference was not statistically significant (p = 0.155). A statistically significant difference was observed in context with disease-free survival (45.2 months, 95% confidence interval 31.7–58.8 months vs. 114.8 months, 95% confidence interval 79.3–150.4 months; p = 0.029). Conclusion: Our study suggests a potential prognostic value of serum albumin in patients with a head and neck ACC. A further, external validation of our results is warranted. MDPI 2022-01-17 /pmc/articles/PMC8774260/ /pubmed/35052870 http://dx.doi.org/10.3390/biomedicines10010191 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Friedl, Marlene
Stoiber, Stefan
Brkic, Faris F.
Kadletz-Wanke, Lorenz
Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
title Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
title_full Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
title_fullStr Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
title_full_unstemmed Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
title_short Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
title_sort pretherapeutic serum albumin as an outcome prognosticator in head and neck adenoid-cystic carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774260/
https://www.ncbi.nlm.nih.gov/pubmed/35052870
http://dx.doi.org/10.3390/biomedicines10010191
work_keys_str_mv AT friedlmarlene pretherapeuticserumalbuminasanoutcomeprognosticatorinheadandneckadenoidcysticcarcinoma
AT stoiberstefan pretherapeuticserumalbuminasanoutcomeprognosticatorinheadandneckadenoidcysticcarcinoma
AT brkicfarisf pretherapeuticserumalbuminasanoutcomeprognosticatorinheadandneckadenoidcysticcarcinoma
AT kadletzwankelorenz pretherapeuticserumalbuminasanoutcomeprognosticatorinheadandneckadenoidcysticcarcinoma